Less than 10% of individuals who could benefit from GLP-1 drugs such as Wegovy are able to get them, caution the global health agency as it releases its initial recommendations on the therapies.
With over a billion individuals worldwide now classified as obese, it is urging increased and just availability to these injectable treatments.
Per forecasts, more than two billion could be living with obesity by 2030 unless action is taken.
"The new guidelines affirms that excess weight is a lifelong illness that can be treated with thorough and ongoing treatment," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are significant obstacles to broad availability to the treatments that can help people shift significant body mass, says the body.
Skinny Jab Scarcity
Even in the current most favorable case, the production of GLP-1 therapies could only cover about 100 million people – less than 10% of those who need them, as stated by the health organization.
The advice calls on countries and companies to increase access, via strategies like patent sharing.
The intellectual property rights on the active ingredient – the main ingredient of a leading brand – is scheduled to end in several nations in 2026.
How Obesity Jabs Function
These medications imitate a natural hormone to delay gastric emptying, suppress the appetite and boost feelings of fullness so users reduce food intake.
Patients commonly begin shedding pounds within a few weeks of commencing the weekly injections.
Evidence indicates users may regain a significant portion within a year of stopping the drug, when their usual appetite come back.
Being above a healthy weight raises your chance for developing health problems, like type 2 diabetes, cardiovascular issues, stroke, and certain malignancies.
Obesity impacts people in all nations and was linked to 3.7 million fatalities worldwide in 2024, according to the WHO.
